Ads
related to: merck- Cell Therapy Production
Cell Therapy Manufacturing Services
From Clinical To Commercial
- AAV Reference Standards
Essential AAV Reference Standards
Full & Empty Capsids of 6 Serotypes
- GMP Retrovirus Services
cGMP-compliant & fully scalable
Viral vector manufacturing
- GMP QC Services
Viral Vector & Plasmid Assays
Quality, Sterility & Potency
- Cell Therapy Production
Search results
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report...
Benzinga· 11 hours agoWestern pharmaceutical companies and investors are driving a record number of licensing deals with...
Are Investors Undervaluing Merck KGaA (ETR:MRK) By 29%?
Simply Wall St. via Yahoo Finance· 2 days agoKey Insights The projected fair value for Merck KGaA is €236 based on 2 Stage Free Cash Flow to...
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 2 days agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
Hedge Funds Are Loading Up On This Dividend Stock
Benzinga via Yahoo Finance· 6 hours agoThe markets are adjusting to the high interest rates environment, with all the major US stock indices reporting strong gains in May 2024. However, even...
How Trump's presidency became a roller-coaster ride for many of America's top CEOs
INSIDER via Yahoo News· 6 days agoThen-Merck CEO Kenneth Frazier listens at right as then-President Donald Trump speaks during a...
Dow Jones Futures Rise With U.S. Markets Shut; 7 Stocks Near Buy Points
Investor's Business Daily· 5 hours agoThe Dow Jones and Russell 2000 had solid losses as consumer, housing, commodity and software names...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%
Simply Wall St. via Yahoo Finance· 5 days agoKey Insights Institutions' substantial holdings in Merck implies that they have significant...
Merck KGaA to buy gene therapy tools maker for $600M
BioPharma Dive via Yahoo Finance· 4 days agoDive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical part of viral vector-based gene therapy...
McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI
VentureBeat· 4 days agoAtropos Health, a healthcare technology company focused on generating personalized real-world...
Merck’s MilliporeSigma agrees to acquire Mirus Bio for $600m
Pharmaceutical Technology via Yahoo Finance· 4 days agoMerck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive...